Metabolic syndrome in HIV-infected patients receiving antiretroviral therapy in Latin America

Detalhes bibliográficos
Autor(a) principal: Alvarez,C
Data de Publicação: 2010
Outros Autores: Salazar,R, Galindez,J, Rangel,F, Castañeda,ML, Lopardo,G, Cuhna,CA, Roldan,Y, Sussman,O, Gutierrez,G, Cure-Bolt,N, Seas,C, Carcamo,C, Castrillo,M
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Journal of Infectious Diseases
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702010000300010
Resumo: OBJECTIVE: To evaluate the prevalence of and the associated factors for metabolic syndrome (MS) among Latin American HIV-infected patients receiving antiretroviral therapy (ART) using baseline data from the RAPID II study. METHODS: A longitudinal study to evaluate the metabolic profile, cardiovascular disease (CVD) risk and associated treatment practices to reduce this risk has been conducted in seven Latin American countries (the RAPID II study). Adult HIV patients with at least six months of RT were enrolled. MS was defined following ATP-III criteria. Demographic and anthropometric data, serum biochemical and clinical parameters were compared in patients with and without MS using bivariate and multivariate analysis. RESULTS: A total of 4,010 patients were enrolled, 2,963 (74%) were males. Mean age (SD) was 41.9 (10.0) years. The prevalence of MS was 20.2%. Females had higher prevalence of MS than males (22.7% vs. 19.4%, p = 0.02). MS was driven by high triglycerides, low HDL-cholesterol and high blood pressure (HBP). Patients with MS had higher 10year CVD risk: 22.2% vs. 7.4%, p < 0.001. Age (OR: 1.05 per year), female gender (OR: 1.29), family history of CVD (OR: 1.28), CD4 cell count (OR: 1.09 per 100 cell increase), and protease inhibitor based-ART (OR: 1.33) correlated with MS in the multivariate analysis. CONCLUSIONS: Prevalence of MS in this setting was similar to that reported from developed countries. MS was driven by high triglycerides, low-HDL and HBP, and it was associated with higher risk of CVD. Traditional risk factors, female gender, immune reconstitution, and protease inhibitor based-ART correlated with MS.
id BSID-1_ad4ffae7d75318a9c9d5059477d40b53
oai_identifier_str oai:scielo:S1413-86702010000300010
network_acronym_str BSID-1
network_name_str Brazilian Journal of Infectious Diseases
repository_id_str
spelling Metabolic syndrome in HIV-infected patients receiving antiretroviral therapy in Latin Americametabolic syndrome (MS)HIVARTLatin AmericaOBJECTIVE: To evaluate the prevalence of and the associated factors for metabolic syndrome (MS) among Latin American HIV-infected patients receiving antiretroviral therapy (ART) using baseline data from the RAPID II study. METHODS: A longitudinal study to evaluate the metabolic profile, cardiovascular disease (CVD) risk and associated treatment practices to reduce this risk has been conducted in seven Latin American countries (the RAPID II study). Adult HIV patients with at least six months of RT were enrolled. MS was defined following ATP-III criteria. Demographic and anthropometric data, serum biochemical and clinical parameters were compared in patients with and without MS using bivariate and multivariate analysis. RESULTS: A total of 4,010 patients were enrolled, 2,963 (74%) were males. Mean age (SD) was 41.9 (10.0) years. The prevalence of MS was 20.2%. Females had higher prevalence of MS than males (22.7% vs. 19.4%, p = 0.02). MS was driven by high triglycerides, low HDL-cholesterol and high blood pressure (HBP). Patients with MS had higher 10year CVD risk: 22.2% vs. 7.4%, p < 0.001. Age (OR: 1.05 per year), female gender (OR: 1.29), family history of CVD (OR: 1.28), CD4 cell count (OR: 1.09 per 100 cell increase), and protease inhibitor based-ART (OR: 1.33) correlated with MS in the multivariate analysis. CONCLUSIONS: Prevalence of MS in this setting was similar to that reported from developed countries. MS was driven by high triglycerides, low-HDL and HBP, and it was associated with higher risk of CVD. Traditional risk factors, female gender, immune reconstitution, and protease inhibitor based-ART correlated with MS.Brazilian Society of Infectious Diseases2010-06-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702010000300010Brazilian Journal of Infectious Diseases v.14 n.3 2010reponame:Brazilian Journal of Infectious Diseasesinstname:Brazilian Society of Infectious Diseases (BSID)instacron:BSID10.1590/S1413-86702010000300010info:eu-repo/semantics/openAccessAlvarez,CSalazar,RGalindez,JRangel,FCastañeda,MLLopardo,GCuhna,CARoldan,YSussman,OGutierrez,GCure-Bolt,NSeas,CCarcamo,CCastrillo,Meng2010-09-09T00:00:00Zoai:scielo:S1413-86702010000300010Revistahttps://www.bjid.org.br/https://old.scielo.br/oai/scielo-oai.phpbjid@bjid.org.br||lgoldani@ufrgs.br1678-43911413-8670opendoar:2010-09-09T00:00Brazilian Journal of Infectious Diseases - Brazilian Society of Infectious Diseases (BSID)false
dc.title.none.fl_str_mv Metabolic syndrome in HIV-infected patients receiving antiretroviral therapy in Latin America
title Metabolic syndrome in HIV-infected patients receiving antiretroviral therapy in Latin America
spellingShingle Metabolic syndrome in HIV-infected patients receiving antiretroviral therapy in Latin America
Alvarez,C
metabolic syndrome (MS)
HIV
ART
Latin America
title_short Metabolic syndrome in HIV-infected patients receiving antiretroviral therapy in Latin America
title_full Metabolic syndrome in HIV-infected patients receiving antiretroviral therapy in Latin America
title_fullStr Metabolic syndrome in HIV-infected patients receiving antiretroviral therapy in Latin America
title_full_unstemmed Metabolic syndrome in HIV-infected patients receiving antiretroviral therapy in Latin America
title_sort Metabolic syndrome in HIV-infected patients receiving antiretroviral therapy in Latin America
author Alvarez,C
author_facet Alvarez,C
Salazar,R
Galindez,J
Rangel,F
Castañeda,ML
Lopardo,G
Cuhna,CA
Roldan,Y
Sussman,O
Gutierrez,G
Cure-Bolt,N
Seas,C
Carcamo,C
Castrillo,M
author_role author
author2 Salazar,R
Galindez,J
Rangel,F
Castañeda,ML
Lopardo,G
Cuhna,CA
Roldan,Y
Sussman,O
Gutierrez,G
Cure-Bolt,N
Seas,C
Carcamo,C
Castrillo,M
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Alvarez,C
Salazar,R
Galindez,J
Rangel,F
Castañeda,ML
Lopardo,G
Cuhna,CA
Roldan,Y
Sussman,O
Gutierrez,G
Cure-Bolt,N
Seas,C
Carcamo,C
Castrillo,M
dc.subject.por.fl_str_mv metabolic syndrome (MS)
HIV
ART
Latin America
topic metabolic syndrome (MS)
HIV
ART
Latin America
description OBJECTIVE: To evaluate the prevalence of and the associated factors for metabolic syndrome (MS) among Latin American HIV-infected patients receiving antiretroviral therapy (ART) using baseline data from the RAPID II study. METHODS: A longitudinal study to evaluate the metabolic profile, cardiovascular disease (CVD) risk and associated treatment practices to reduce this risk has been conducted in seven Latin American countries (the RAPID II study). Adult HIV patients with at least six months of RT were enrolled. MS was defined following ATP-III criteria. Demographic and anthropometric data, serum biochemical and clinical parameters were compared in patients with and without MS using bivariate and multivariate analysis. RESULTS: A total of 4,010 patients were enrolled, 2,963 (74%) were males. Mean age (SD) was 41.9 (10.0) years. The prevalence of MS was 20.2%. Females had higher prevalence of MS than males (22.7% vs. 19.4%, p = 0.02). MS was driven by high triglycerides, low HDL-cholesterol and high blood pressure (HBP). Patients with MS had higher 10year CVD risk: 22.2% vs. 7.4%, p < 0.001. Age (OR: 1.05 per year), female gender (OR: 1.29), family history of CVD (OR: 1.28), CD4 cell count (OR: 1.09 per 100 cell increase), and protease inhibitor based-ART (OR: 1.33) correlated with MS in the multivariate analysis. CONCLUSIONS: Prevalence of MS in this setting was similar to that reported from developed countries. MS was driven by high triglycerides, low-HDL and HBP, and it was associated with higher risk of CVD. Traditional risk factors, female gender, immune reconstitution, and protease inhibitor based-ART correlated with MS.
publishDate 2010
dc.date.none.fl_str_mv 2010-06-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702010000300010
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702010000300010
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S1413-86702010000300010
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Brazilian Society of Infectious Diseases
publisher.none.fl_str_mv Brazilian Society of Infectious Diseases
dc.source.none.fl_str_mv Brazilian Journal of Infectious Diseases v.14 n.3 2010
reponame:Brazilian Journal of Infectious Diseases
instname:Brazilian Society of Infectious Diseases (BSID)
instacron:BSID
instname_str Brazilian Society of Infectious Diseases (BSID)
instacron_str BSID
institution BSID
reponame_str Brazilian Journal of Infectious Diseases
collection Brazilian Journal of Infectious Diseases
repository.name.fl_str_mv Brazilian Journal of Infectious Diseases - Brazilian Society of Infectious Diseases (BSID)
repository.mail.fl_str_mv bjid@bjid.org.br||lgoldani@ufrgs.br
_version_ 1754209241171755008